Form 4: Cross Country Healthcare Director Receives Equity Grant

Cross Country Healthcare Director W. Larry Cash was granted 18,680 restricted shares of common stock, vesting on December 18, 2025, following a merger termination.

Summary

• W. Larry Cash, a Director of Cross Country Healthcare Inc. (CCRN), is scheduled to acquire 18,680 restricted shares of common stock.
• The transaction date for this acquisition is December 18, 2025, and the shares will vest on the same date.
• The shares were acquired at a price of $0, indicating a grant.
• Following this transaction, W. Larry Cash will beneficially own 223,312 shares of common stock.
• The grant was approved by the Compensation Committee of the Company's Board of Directors.
• The timing of the grant (December 18, 2025, instead of March 31, 2025) follows the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.
• The transaction is made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The grant of restricted shares to a director is a positive for aligning management interests with shareholders, but it is a routine compensation event and does not indicate significant new operational news.

Positives

• Director W. Larry Cash received a grant of 18,680 restricted shares, which aligns his interests with shareholders.
• The grant demonstrates continued commitment to executive compensation and retention strategies.

Negatives

• NA

Risks

• The filing mentions the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025. While not a direct risk from this grant, the termination of a merger agreement can imply strategic shifts or missed opportunities for the company.

Future Outlook

The filing reports a future grant of 18,680 restricted shares to Director W. Larry Cash on December 18, 2025, which will also vest on that date. This transaction is pursuant to a Rule 10b5-1(c) plan.

Management Comments

• The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.

Industry Context

This is a standard equity grant for a director in the healthcare staffing industry. The mention of a terminated merger could indicate a strategic pivot or a return to organic growth focus for Cross Country Healthcare, which operates in a competitive and dynamic sector.

Comparison to Industry Standards

• Equity grants to directors are a common practice across industries, including healthcare, to align leadership incentives with shareholder value. The specific terms, such as the number of shares and vesting schedule, are typically determined by the compensation committee based on performance, market benchmarks, and retention goals. No specific comparable companies or projects are mentioned in the filing to allow for a direct quantitative comparison.

Corporate Governance

Related Party Transactions

• The grant of 18,680 restricted shares of common stock to Director W. Larry Cash constitutes a related party transaction, which is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The grant of restricted shares to Director W. Larry Cash further aligns his financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on customers, suppliers, or creditors is mentioned in this filing.

Next Steps

• Vesting of 18,680 restricted shares on December 18, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to an existing director, which aligns management interests with shareholders. It does not contain new operational or financial information that would warrant a change in investment recommendation based solely on this disclosure. The mention of a terminated merger is contextual for the grant timing, not new news impacting the stock price.

Keywords

Cross Country Healthcare, CCRN, W. Larry Cash, Form 4, Restricted Stock, Equity Grant, Director Compensation, Insider Transaction, Merger Termination, Rule 10b5-1